Melatonin: A Potential Anti-Oxidant Therapeutic Agent for Mitochondrial Dysfunctions and Related Disorders
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Mitochondria play a central role in cellular physiology. Besides their classic function of energy metabolism, mitochondria are involved in multiple cell functions, including energy distribution through the cell, energy/heat modulation, regulation of reactive oxygen species (ROS), calcium homeostasis, and control of apoptosis. Simultaneously, mitochondria are the main producer and target of ROS with the result that multiple mitochondrial diseases are related to ROS-induced mitochondrial injuries. Increased free radical generation, enhanced mitochondrial inducible nitric oxide synthase (iNOS) activity, enhanced nitric oxide (NO) production, decreased respiratory complex activity, impaired electron transport system, and opening of mitochondrial permeability transition pores have all been suggested as factors responsible for impaired mitochondrial function. Because of these, neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and aging, are caused by ROS-induced mitochondrial dysfunctions. Melatonin, the major hormone of the pineal gland, also acts as an anti-oxidant and as a regulator of mitochondrial bioenergetic function. Melatonin is selectively taken up by mitochondrial membranes, a function not shared by other anti-oxidants, and thus has emerged as a major potential therapeutic tool for treating neurodegenerative disorders. Multiple in vitro and in vivo experiments have shown the protective role of melatonin for preventing oxidative stress–induced mitochondrial dysfunction seen in experimental models of PD, AD, and HD. With these functions in mind, this article reviews the protective role of melatonin with mechanistic insights against mitochondrial diseases and suggests new avenues for safe and effective treatment modalities against these devastating neurodegenerative diseases. Future insights are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Regulation of cellular metabolism by protein lysine acetylation
Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., Yao, J., Zhou, L., Zeng, Y., Li, H., et al. (2010) · Science · doi:10.1126/science.1179689 · Cited by 1,910 · cited 1×
“163 Three mitochondrial de-acetylation enzymes have been identified, namely sirtuin-3, sirtuin-4, and sirtuin-5 (SIRT3–5), 164 with SIRT3 being found to be the most robust mitochondrial deacetylase.”
Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation
Lombard, D. B., Alt, F. W., Cheng, H.-L., Bunkenborg, J., Streeper, R. S., Mostoslavsky, R., Kim, J., Yancopoulos, G., Valenzuela, D., Murphy, A., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01636-07 · Cited by 1,216 · cited 1×
“162,165 In addition to its established mitochondrial function, SIRT3 is also a nuclear NAD + -dependent histone deacetylase that translocates to the mitochondria in response to various stressors, including ultraviolet (UV) irradiation and the chemotherapeutic drug etoposide.”
Mitochondria in neuroplasticity and neurological disorders
Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081 · cited 1×
“203 Following oxidative stress, the increase in Ca 2 + uptake in mitochondria of AD fibroblasts is much greater than that in controls, indicating that mitochondria from AD fibroblasts have a higher sensitivity toward oxidative stress.”
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927 · cited 3×
“Complex I inhibition and oxidative stress were shown to be relevant to naturally occurring PD when Complex I deficiency and GSH depletion were found in the sub-stantia nigra of patients with idiopathic PD and in patients with pre-symptomatic PD. 224 The increased incidence of age-associated neurodegenerative diseases s…”
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 1×
“,69,70 These investigations were conducted using pure chemical systems, in vitro –cultured cells, and in vivo and in silico methodologies.”
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869 · cited 1×
“182 HD is a neurodegenerative disorder characterized by ataxia, chorea, and dementia.”
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
Cited by
Melatonin: an ancient molecule that makes oxygen metabolically tolerable
Manchester, L. C., Coto‐Montes, A., Boga, J. A., Andersen, L. P. H., Zhou, Z., Galano, A., Vriend, J., Tan, D., & Reiter, R. J. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12267 · Cited by 945
Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics
Tan, D.-X., Manchester, L., Qin, L., & Reiter, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122124 · Cited by 402
“These include, but are not limited to, a reduction of mitochondrial oxidative stress [150,151], preservation of the mitochondrial membrane potential [152–154], upregulation of the antiapoptotic mitochondrial protein/downregulation of the proapoptotic mitochondrial protein, Bax [137,155,156], increased efficiency of AT…”
An Overview of NO Signaling Pathways in Aging
Pourbagher-Shahri, A. M., Farkhondeh, T., Talebi, M., Kopustinskiene, D. M., Samarghandian, S., & Bernatoniene, J. (2021) · Molecules · doi:10.3390/molecules26154533 · Cited by 101
“In a rat study of sepsis, melatonin (y′) could efficiently reduce the aging-promoted iNOS expression [302,303].”
BackgroundFarias, T. D. S. M. D., Cruz, M. M., Sa, R. C. D. C. D., Severi, I., Perugini, J., Senzacqua, M., Cerutti, S. M., Giordano, A., Cinti, S., & Alonso-Vale, M. I. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00750 · Cited by 74
Metadata
- Authors
- Ganie, S. A., Dar, T. A., Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., & Masood, A.
- Venue
- Rejuvenation Research
- Publisher
- SAGE Publications
- Published
- 2016-02
- Volume
- 19
- Issue
- 1
- Pages
- 21-40
- ISSN
- 1094-5458 (ISSN-L)
- 1549-1684
- 1557-8577
- OpenAlex
- W2111841370
- Cited by
- 79
- References
- 22
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.